Skip redundant pieces
University of Kansas Cancer Center
University of Kansas Cancer Center  :  Leadership

Karen L. Kelly, MD


K KellyDeputy Director, University of Kansas Cancer Center
Associate Director, Clinical Research
Frank B. Tyler Cancer Research Professor
kkelly@kumc.edu

Karen Kelly, MD, is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through clinical trials to everyone throughout the region.

Since becoming deputy director in 2006, she has built the clinical trials infrastructure that has revitalized the clinical trials program to better serve patients and streamline the process for physicians. 

Dr. Kelly has been at the forefront in the development of numerous clinical trials evaluating anticancer agents, primarily for small-cell and non-small-cell lung cancer (NSCLC).  Widely published, Dr. Kelly has authored or coauthored nearly 100 publications. 

Background

A native of Derby, Kansas, Dr. Kelly received her undergraduate degree from Emporia State University.  She went on to receive her medical degree from the University of Kansas School of Medicine.  Dr. Kelly  did her fellowship  in hematology/oncology at the University of Colorado Health Sciences Center.  Dr. Kelly served 16 years at the University of Colorado’s Health Sciences Center.  Additionally, she served as the director of the clinical lung cancer program  for the University of Colorado’s Comprehensive Cancer Center. 

University of Kansas Cancer Center

Dr. Kelly assumed the deputy director position of KUCC in October 2006.  She is the recipient of the Frank B. Tyler professorship.

Membership Organizations

  • Member, American Society of Clinical Oncology, Nominating Committee
  • Member, Southwest Oncology Group; Vice Chair, Lung Cancer Committee
  • Member, International Association for the Study of Lung Cancer: Chair, Young Investigators Awards
  • Member, National Lung Cancer Partnership, Scientific Committee

Recent Publications

  1. Hirsch F, Herbst R, Olsen C, Chansky K, Crowley J, Kelly K, Franklin W, Bunn Jr. P, Varella-Garcia M, Gandara D. Increased EGFR gene copy number detected by FISH predicts outcome in NSCLC patients treated with cetuximab and chemotherapy. Submitted to J Clin Oncol August 2007.
  2. Weiss G, Zeng C, Kelly K, Tran Z, Bunn Jr. P. Single institution experience with pemetrexed and bevacizumab as salvage therapy in advanced NSCLC. Clinical Lung Ca: 1-4, 2007.
  3. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidia P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortexomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24(11): 711-4, 2006.
  4. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A Prognostic Model for Advanced Stage Non-small Cell Lung Cancer. Pooled Analysis of North Central Cancer Treatment Group Trials. Cancer 107(4):781-92, 2006.
  5. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S McAndrews P, Bunn PA Jr, Kelly K. Elderly Patients Benefit from Second –Line Cytotoxic Chemotherapy; A Subset Analysis of a Randomized phase III Trial of Pemetrexed compared with Docetaxel in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 24(27):4405-11, 2006.
  6. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN Jr, Kelly K, Crowley J, Livingston R. Long-Term Survival with Concurrent Chemoradiation Therapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small-Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 8(2):116-21, 2006.
  7. Fanucchi M, Belt R, Fossella F, Natale R, Robert F, Fidias P, Kelly K, Kashala O, Schenkein D, Schiller J.  Bortezomib ± Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer:  Interim Analysis of a Phase 2 Study.  J Clin Onc 24(31): 5025-33, 2006.
  8. Mandrekar, SJ, Schild, SE, Hillman, SL, Allen, KL, Marks, RS, Mailliard, JA, Krook, JE, Maksymiuk, AW, Crowley, J, Kelly, K, Adjel, AA, Jett, JR:  A Prognostic Model for Advanced Stage Non-Small Cell Lung Cancer:  Pooled Analysis of NCCTG Trials.  Cancer, [Epub ahead of print, July, 2006].
  9. Govindan, R, Natale, R, Wade, J, Herbst, R, Krebs, A, Reiling, R, Hensing, T, Wozniak, A, Belani, CP, Kelly, K, Ochs, J:  Efficacy and Safety of Gefitinib in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer Treated in an Expanded Access Program.  Lung Cancer Journal, 53(3):331-7, 2006 [Epub ahead of print, June, 2006].
  10. Bunn, PA Jr, Dziadziuszko, R, Varella-Garcia, M, Franklin, WA, Witta, SE, Kelly, K, Hirsch, FR:  Biological Markers for Non-small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.  Clinical Cancer Res, 15:12(12):3652-6, 2006.